Medolife Rx Completes Initial Meeting with Bioethics Committee, Preparing for Commencement of Phase II Clinical Trial on Lead Drug Candidate
May 20, 2021 08:00 ET | Source: Quanta, Inc. Quanta, Inc.
BURBANK, Calif., May 20, 2021 (GLOBE NEWSWIRE) via NewMediaWire – Medolife Rx, Inc. ( Medolife ), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it completed its initial meetings with CONABIOS, the medical ethics committee that oversees all clinical trial programs in the Dominican Republic (DR). The meeting outlined the next steps in its clinical program on Escozine® as a treatment for the SARS-CoV-2 (COVID-19) virus and the Company is seeking approval to commence clinical trials.
Medolife Rx Announces New Extraction Facility and Scientific Team in Place
May 13, 2021 08:00 ET | Source: Quanta, Inc. Quanta, Inc.
BURBANK, Calif., May 13, 2021 (GLOBE NEWSWIRE) via
NewMediaWire Medolife Rx, Inc. ( Medolife ), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that it has secured a new extraction facility in the Dominican Republic (DR) as well as onboarded scientific staff in order to increase production of Escozine® to meet rising demand following the Company’s recent product registration as a natural alternative cancer treatment.
Medolife Rx’s Lead Drug Candidate Escozine® Recommended by Doctor for Use in Cancer Treatment Regimen in Dominican Republic
April 01, 2021 09:00 ET | Source: Quanta, Inc. Quanta, Inc.
BURBANK, Calif., April 01, 2021 (GLOBE NEWSWIRE) via
NewMediaWire Medolife Rx, Inc. ( Medolife ), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that Dr. Ramón Feliz MD, PhD, an oncological surgeon practicing medicine in the Dominican Republic, has made an official recommendation for inclusion of Medolife’s drug candidate Escozine® in treatment regimens for patients with various forms of cancer including pancreatic, breast, prostate, and different segments of colon cancer.